FLULAVAL description, usages, side effects, indications, overdosage, supplying and lots more!

FLULAVAL

ID Biomedical Corporation of Quebec

  • Description
  • Clinical Pharmacology
  • Indications & Usage
  • Contraindications
  • Warnings
  • Precautions
  • Side Effects
  • Overdosage
  • Dosage & Administration
  • How Supplied
  • Patient Counseling Information
  • Supplemental Patient Material
  • Boxed Warning
  • Patient Package Insert
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use FLULAVAL safely and effectively. See full prescribing information for FLULAVAL. FLULAVAL (Influenza Virus Vaccine)Suspension for Intramuscular Injection2013-2014 FormulaInitial U.S. Approval: 2006

RECENT MAJOR CHANGES

Indications and Usage (1)08/2013Dosage and Administration (2.1)08/2013
 
 
 
 

INDICATIONS AND USAGE

  • •FLULAVAL is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. FLULAVAL is approved for use in persons 3 years of age and older. (1)

DOSAGE AND ADMINISTRATION

For intramuscular injection only. (2)

AgeVaccination StatusDose and Schedule3 through 8 years of ageNot previously vaccinated with influenza vaccineTwo doses (0.5‑mL each) at least 4 weeks apart (2.1)Vaccinated with influenza vaccine in a previous seasonOne or two dosesa
  • (0.5‑mL each) (2.1)9 years of age and olderNot applicableOne 0.5‑mL dose (2.1)
     
     
     
     
     
     
     
       
     
     
     

    a One dose or two doses (0.5-mL each) depending on vaccination history as per the annual Advisory Committee on Immunization Practices (ACIP) recommendation on prevention and control of influenza with vaccines. If two doses administer each 0.5 mL dose at least 4 weeks apart. (2.1)

    DOSAGE FORMS AND STRENGTHS

    Suspension for injection in 5-mL multi-dose vials containing ten 0.5 mL doses. (3)

    CONTRAINDICATIONS

    History of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine. (4, 11)

    WARNINGS AND PRECAUTIONS

    • •If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLULAVAL should be based on careful consideration of the potential benefits and risks. (5.1)
    • •Syncope (fainting) can occur in association with administration of injectable vaccines, including FLULAVAL. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope. (5.2)

    Side Effects

    • •In adults, the most common (≥10%) solicited local adverse reactions were pain (51%), redness (13%), and/or swelling (11%); the most common solicited systemic adverse events were fatigue (20%), headache (18%), and muscle aches/arthralgia (18%). (6.1)
    • •In children 3 through 17 years of age, the most common (≥10%) solicited local adverse reaction was pain (56%). (6.1)
    • •In children 3 through 4 years of age, the most common (≥10%) solicited systemic adverse events were irritability (25%), drowsiness (19%), and loss of appetite (16%). (6.1)
    • •In children 5 through 17 years of age, the most common (≥10%) solicited systemic adverse events were muscle aches (24%), headache (17%), and fatigue (17%). (6.1)

    To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

    USE IN SPECIFIC POPULATIONS

    • •Safety and effectiveness of FLULAVAL have not been established in pregnant women or nursing mothers. (8.1, 8.3)
    • •Register women who receive FLULAVAL while pregnant in the pregnancy registry by calling 1-888-452-9622. (8.1)
    • •Geriatric Use: Antibody responses were lower in geriatric subjects who received FLULAVAL than in younger subjects. (8.5)

    FULL PRESCRIBING INFORMATION: CONTENTS*




    FULL PRESCRIBING INFORMATION

    1 INDICATIONS AND USAGE

    FLULAVAL® is indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. FLULAVAL is approved for use in persons 3 years of age and older.

    2 DOSAGE AND ADMINISTRATION

    For intramuscular injection only.

    2.1 Dosage and Schedule

    The dose and schedule for FLULAVAL are presented in Table 1.

    Table 1. FLULAVAL: Dosing

    Age

    Vaccination Status

    Dose and Schedule

    3 through 8 years of age

    Not previously vaccinated with influenza vaccine

    Two doses (0.5‑mL each) at least 4 weeks apart

    Vaccinated with influenza vaccine in a previous season

    One or two dosesa (0.5‑mL each)

    9 years of age and older

    Not applicable

    One 0.5‑mL dose

    a One dose or two doses (0.5‑mL each) depending on vaccination history as per the annual Advisory Committee on Immunization Practices (ACIP) recommendation on prevention and control of influenza with vaccines. If two doses, administer each 0.5‑mL dose at least 4 weeks apart.

    2.2 Administration Instructions

    Shake the multi-dose vial vigorously each time before withdrawing a dose of vaccine. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.

    Use a sterile needle and sterile syringe to withdraw the 0.5‑mL dose from the multi-dose vial and administer intramuscularly. A sterile syringe with a needle bore no larger than 23 gauge is recommended for administration. It is recommended that small syringes (0.5-mL or 1-mL) be used to minimize any product loss. Use a separate sterile needle and syringe for each dose withdrawn from the multi-dose vial.

    The preferred site for intramuscular injection is the deltoid muscle of the upper arm. Do not inject in the gluteal area or areas where there may be a major nerve trunk.

    Between uses, return the multi-dose vial to the recommended storage conditions, between 2º and 8ºC (36º and 46ºF). Do not freeze. Discard if the vaccine has been frozen. Once entered, a multi-dose vial, and any residual contents, should be discarded after 28 days.

    Do not administer this product intravenously, intradermally, or subcutaneously.

    3 DOSAGE FORMS AND STRENGTHS

    FLULAVAL is a suspension for injection available in 5-mL multi-dose vials containing ten 0.5 mL doses.

    4 CONTRAINDICATIONS

    Do not administer FLULAVAL to anyone with a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine.

    5 WARNINGS AND PRECAUTIONS

    5.1 Guillain-Barré Syndrome

    If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLULAVAL should be based on careful consideration of the potential benefits and risks.

    The 1976 swine influenza vaccine was associated with an elevated risk of GBS. Evidence for a causal relation of GBS with other influenza vaccines is inconclusive; if an excess risk exists, it is probably slightly more than one additional case/one million persons vaccinated.

    5.2 Syncope

    Syncope (fainting) can occur in association with administration of injectable vaccines, including FLULAVAL. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.

    5.3 Preventing and Managing Allergic Vaccine Reactions

    Prior to administration, the healthcare provider should review the immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of FLULAVAL.

    5.4 Altered Immunocompetence

    If FLULAVAL is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons.

    5.5 Limitations of Vaccine Effectiveness

    Vaccination with FLULAVAL may not protect all susceptible individuals.

    5.6 Persons at Risk of Bleeding

    As with other intramuscular injections, FLULAVAL should be given with caution in individuals with bleeding disorders such as hemophilia or on anticoagulant therapy to avoid the risk of hematoma following the injection.

    6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    In adults who received FLULAVAL, the most common (≥10%) solicited local adverse reactions were pain (51%), redness (13%), and swelling (11%); the most common (≥10%) solicited systemic adverse events were fatigue (20%), headache (18%), and muscle aches/arthralgia (18%).

    In children 3 through 17 years of age who received FLULAVAL, the most common (≥10%) solicited local adverse reaction was pain (56%). In children 3 through 4 years of age, the most common (≥10%) solicited systemic adverse events were irritability (25%), drowsiness (19%), and loss of appetite (16%). In children 5 through 17 years of age, the most common (≥10%) systemic adverse events were muscle aches (24%), headache (17%), and fatigue (17%).

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine, and may not reflect the rates observed in practice. There is the possibility that broad use of FLULAVAL could reveal adverse reactions not observed in clinical trials.

    FLULAVAL in Adults: Safety data was obtained from 3 randomized, controlled trials, one of which was a placebo-controlled efficacy study. In these trials, 9,836 subjects were randomized to receive either FLULAVAL (5,114 subjects in the safety analysis), FLUZONE, a US‑licensed trivalent, inactivated influenza virus vaccine, manufactured by Sanofi Pasteur SA (894 subjects in the safety analysis), or placebo (3,828 subjects in the safety analysis), intramuscularly. In these studies, solicited events were collected for 4 days (i.e., 30 minutes post-vaccination through the next 3 days). Unsolicited adverse events that occurred within 22 days of vaccination (day 0‑21) were recorded based on spontaneous reports or in response to queries about changes in health status.

    Study 1 (Immunogenicity): Safety information was collected in a randomized, controlled US study. This study included 1,000 adults 18 through 64 years of age who were randomized to receive FLULAVAL (N = 721) or a US‑licensed trivalent, inactivated influenza virus vaccine (N = 279). Among recipients of FLULAVAL, 57% were female; 91% of subjects were white and 9% were of other racial/ethnic groups. The mean age of subjects was 38 years; 80% were 18 through 49 years of age and 20% were 50 through 64 years of age.

    Study 2 (Immunogenicity Non-Inferiority): Safety information was collected in a randomized, double-blind, active-controlled US study. The study included 1,225 adults ≥50 years of age randomized to receive FLULAVAL (N = 610) or a US‑licensed trivalent, inactivated influenza virus vaccine (N = 615). In the total population, 57% were female; 95% of subjects were white and 5% were of other racial/ethnic groups. The mean age of subjects was 66 years (46% were 50 through 64 years of age, 41% were 65 through 79 years of age, and 13% were ≥80 years of age).

    Study 3 (Efficacy): Safety information was collected in a double-blind, placebo-controlled US study. The study included 7,658 adults 18 through 49 years of age randomized to receive FLULAVAL (N = 3,807) or placebo (N = 3,851). In the total population, 61% were female; 84% of subjects were white, 10% black, 2% Asian, and 4% were of other racial/ethnic groups. The mean age of subjects was 33 years.

    Solicited Adverse Events: Solicited local adverse reactions and systemic adverse events collected for 4 days (day of vaccination and the next 3 days) are presented in Table 2.

    PainRednessSwellingHeadacheFatigueMuscle achesdFever (≥99.5°F (37.5°C)MalaiseSore throatReddened eyesCoughChillsChest tightnessFacial swelling
    Table 2. FLULAVAL: Incidence of Solicited Local Adverse Reactions and Systemic Adverse Events Within 4 Daysa of Vaccination in Adults (Total Vaccinated Cohort)

    Percentage of Subjects Reporting Event

    Study 1b

    18 Through 64 Years of Age

    Study 2b

    50 Years of Age and Older

    Study 3b

    18 Through 49 Years of Age

    FLULAVAL

    Comparatorc

    FLULAVAL

    Comparatorc

    FLULAVAL

    Placebo

    N = 721

    N = 279

    N = 610

    N = 615

    N = 3,783

    N = 3,828

    Local Adverse Reactions

     

    24

    31

    25

    32

    51

    14

     

    11

    10

    10

    11

    13

    6

     

    10

    10

    7

    9

    11

    3

    Systemic Adverse Events

     

    18

    17

    11

    12

    18

    19

     

    17

    15

    12

    13

    20

    18

     

    13

    16

    11

    10

    18

    10

     

    11

    10

    1

    1

    3

    1

     

    10

    10

    6

    7

    9

    6

     

    9

    9

    5

    6

    9

    9

     

    6

    5

    4

    7

    7

    6

     

    6

    7

    5

    6

    8

    7

     

    5

    2

    3

    6

    4

    4

     

    3

    1

    2

    2

    3

    3

     

    1

    1

    1

    2

    1

    1

    •  Total vaccinated cohort for safety included all vaccinated subjects for whom safety data were available.
    •   a 4 days included day of vaccination and the subsequent 3 days.
    •   b Study 1: NCT01389479; Study 2: NCT00232947; Study 3: NCT00216242.
    •   c US‑licensed trivalent, inactivated influenza virus vaccine (manufactured by Sanofi Pasteur SA).
    •   d For Study 2 and Study 3, includes muscle aches and arthralgia.

    Unsolicited Adverse Events: The incidence of unsolicited adverse events in the 21 days post-vaccination was comparable for FLULAVAL and the active comparator in Study 1 (16% and 15%, respectively) and in Study 2 (18% and 21%, respectively). In Study 3, the incidence of unsolicited adverse events was comparable for the groups (21% for FLULAVAL and 19% for placebo).

    Unsolicited adverse events defined as reported with FLULAVAL in >1.0% of subjects are described as follows: Study 1: Cough, headache, and pharyngolaryngeal pain; Study 2: Diarrhea, headache, and nasopharyngitis; and Study 3: Pharyngolaryngeal pain, headache, fatigue, cough, injection site pain, upper respiratory tract infection, musculoskeletal pain, nasopharyngitis, injection site erythema and discomfort.

    Serious Adverse Events (SAEs): In Study 1, no SAEs were reported. In Study 2, 3% of subjects receiving FLULAVAL and 3% of subjects receiving the active comparator reported SAEs. In Study 3, 1% of subjects receiving FLULAVAL and 1% of subjects receiving placebo reported SAEs. In the 3 clinical trials, the rates of SAEs were comparable between groups and none of the SAEs were considered related to vaccination.

    FLULAVAL in Children: Study 4 (Immunogenicity Non-Inferiority): An observer-blind, active-controlled US study evaluated subjects 3 through 17 years of age who received FLULAVAL (N = 1,055) or FLUZONE (N = 1,061), a US‑licensed trivalent, inactivated influenza virus vaccine, manufactured by Sanofi Pasteur SA. In the overall population, 53% were male; 78% of subjects were White, 12% were Black, 2% were Asian, and 8% were of other racial/ethnic groups. The mean age of subjects was 8 years. Children 3 through 8 years of age with no history of influenza vaccination received 2 doses approximately 28 days apart. Children 3 through 8 years of age with a history of influenza vaccination and children 9 years of age and older received one dose. Solicited local adverse reactions and systemic adverse events were collected for 4 days (day of vaccination and the next 3 days) (Table 3).

    Table 3. FLULAVAL: Incidence of Solicited Local Adverse Reactions and Systemic Adverse Events Within 4 Daysa of First Vaccination in Children 3 Through 17 Years of Ageb (Total Vaccinated Cohort)

    FLULAVAL

    %

    Active Comparatorc

    %

    3 Through 17 Years of Age

    Local Adverse Reactions

    N = 1,042

    N = 1,026

    Pain

    56

    53

    Redness

    4

    5

    Swelling

    4

    5

    3 Through 4 Years of Age

    Systemic Adverse Events

    N = 293

    N = 279

    Irritability

    25

    27

    Drowsiness

    19

    19

    Loss of appetite

    16

    13

    Fever ≥100.4°F (38.0°C)

    5

    3

    5 Through 17 Years of Age

    Systemic Adverse Events

    N = 750

    N = 747

    Muscle aches

    24

    23

    Headache

    17

    15

    Fatigue

    17

    17

    Arthralgia

    8

    10

    Shivering

    6

    5

    Fever ≥100.4°F (38.0°C)

    5

    4

    Total vaccinated cohort for safety included all vaccinated subjects for whom safety data were available.

    a 4 days included day of vaccination and the subsequent 3 days.

    b Study 4: NCT00980005.

    c US‑licensed trivalent, inactivated influenza virus vaccine (manufactured by Sanofi Pasteur SA).

    In children who received a second dose of FLULAVAL or the comparator vaccine, the incidences of adverse events following the second dose were generally lower than those observed after the first dose.

    The incidence of unsolicited adverse events that occurred within 28 days (day 0-27) of any vaccination reported in subjects who received FLULAVAL (N = 1,055) or FLUZONE (N = 1,061) was 40% and 37%, respectively. The unsolicited adverse events that occurred most frequently (≥0.1% of subjects for FLULAVAL) and considered possibly related to vaccination included diarrhea, influenza-like illness, injection site hematoma, injection site rash, injection site warmth, rash, upper abdominal pain, and vomiting. The rates of SAEs were comparable between groups (0.9% and 0.6% for FLULAVAL and the comparator, respectively); none of the SAEs were considered related to vaccination.

    6.2 Postmarketing Experience

    In addition to reports in clinical trials, the following adverse events have been identified during postapproval use of FLULAVAL. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their incidence rate or establish a causal relationship to the vaccine. Adverse events described here are included because: a) they represent reactions which are known to occur following immunizations generally or influenza immunizations specifically; b) they are potentially serious; or c) the frequency of reporting.

    Blood and Lymphatic System Disorders: Lymphadenopathy.

    Eye Disorders: Eye pain, photophobia.

    Gastrointestinal Disorders: Dysphagia.

    General Disorders and Administration Site Conditions: Chest pain, injection site inflammation, asthenia, injection site rash, abnormal gait, injection site bruising, injection site sterile abscess.

    Immune System Disorders: Allergic reactions including anaphylaxis, angioedema.

    Infections and Infestations: Rhinitis, laryngitis, cellulitis.

    Musculoskeletal and Connective Tissue Disorders: Muscle weakness, arthritis.

    Nervous System Disorders: Dizziness, paresthesia, hypoesthesia, hypokinesia, tremor, somnolence, syncope, Guillain-Barré syndrome, convulsions/seizures, facial or cranial nerve paralysis, encephalopathy, limb paralysis.

    Psychiatric Disorders: Insomnia.

    Respiratory, Thoracic, and Mediastinal Disorders: Dyspnea, dysphonia, bronchospasm, throat tightness.

    Skin and Subcutaneous Tissue Disorders: Urticaria, pruritus, sweating.

    Vascular Disorders: Flushing, pallor.

    7 DRUG INTERACTIONS

    7.1 Concomitant Administration With Other Vaccines

    FLULAVAL should not be mixed with any other vaccine in the same syringe or vial.

    There are insufficient data to assess the concomitant administration of FLULAVAL with other vaccines. When concomitant administration of other vaccines is required, the vaccines should be administered at different injection sites.

    7.2 Immunosuppressive Therapies

    Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to FLULAVAL.

    8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Category B

    A reproductive and developmental toxicity study has been performed in female rats at a dose 40-fold the human dose (on a mg/kg basis) and showed no evidence of impaired female fertility or harm to the fetus due to FLULAVAL. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, FLULAVAL should be given to a pregnant woman only if clearly needed.

    In a reproductive and developmental toxicity study, the effect of FLULAVAL on embryo-fetal and pre-weaning development was evaluated in rats. Animals were administered FLULAVAL by intramuscular injection once prior to gestation, and during the period of organogenesis (gestation days 6, 8, 11, and 15), 0.1 mL/dose/rat (approximately 40-fold higher than the projected human dose on a body weight basis). No adverse effects on mating, female fertility, pregnancy, parturition, lactation parameters, and embryo-fetal or pre-weaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis.

    Pregnancy Registry: GlaxoSmithKline maintains a surveillance registry to collect data on pregnancy outcomes and newborn health status outcomes following vaccination with FLULAVAL during pregnancy. Women who receive FLULAVAL during pregnancy should be encouraged to contact GlaxoSmithKline directly or their healthcare provider should contact GlaxoSmithKline by calling 1-888-452-9622.

    8.3 Nursing Mothers

    It is not known whether FLULAVAL is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when FLULAVAL is administered to a nursing woman.

    8.4 Pediatric Use

    Safety and effectiveness of FLULAVAL in children younger than 3 years of age have not been established.

    Safety and immunogenicity of FLULAVAL in children 3 through 17 years of age have been evaluated [see Adverse Reactions (6.1) and Clinical Studies (14)].

    8.5 Geriatric Use

    In clinical trials, there were 330 subjects 65 years of age and older who received FLULAVAL; 142 of these subjects were 75 years of age and older. Hemagglutination inhibition antibody responses were lower in geriatric subjects than younger subjects after administration of FLULAVAL. [See Clinical Studies (14.2).] Solicited adverse events were similar in frequency to those reported in younger subjects [see Adverse Reactions (6.1)].

    11 DESCRIPTION

    FLULAVAL, Influenza Virus Vaccine, for intramuscular injection, is a trivalent, split-virion, inactivated influenza virus vaccine prepared from virus propagated in the allantoic cavity of embryonated hens’ eggs. Each of the influenza viruses is produced and purified separately. The virus is inactivated with ultraviolet light treatment followed by formaldehyde treatment, purified by centrifugation, and disrupted with sodium deoxycholate.

    FLULAVAL is a sterile, translucent to whitish opalescent suspension in a phosphate-buffered saline solution that may sediment slightly. The sediment resuspends upon shaking to form a homogeneous suspension.

    FLULAVAL has been standardized according to USPHS requirements for the 2013‑2014 influenza season and is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5-mL dose in the recommended ratio of 15 mcg HA of each of the following 3 strains: A/California/7/2009 NYMC X‑179A (H1N1), A/Texas/50/2012 NYMC X-223A (H3N2) (an A/Victoria/361/2011-like virus), and B/Massachusetts/2/2012 NYMC BX-51B.

    Thimerosal, a mercury derivative, is added as a preservative. Each 0.5-mL dose contains 50 mcg thimerosal (<25 mcg mercury). Each 0.5-mL dose may also contain residual amounts of ovalbumin (≤0.3 mcg), formaldehyde (≤25 mcg), and sodium deoxycholate (≤50 mcg) from the manufacturing process. Antibiotics are not used in the manufacture of this vaccine.

    The vial stoppers are not made with natural rubber latex.

    12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Influenza illness and its complications follow infection with influenza viruses. Global surveillance of influenza identifies yearly antigenic variants. Since 1977, antigenic variants of influenza A (H1N1 and H3N2) viruses and influenza B viruses have been in global circulation.

    Specific levels of hemagglutination inhibition (HI) antibody titer post-vaccination with inactivated influenza virus vaccines have not been correlated with protection from influenza illness but the antibody titers have been used as a measure of vaccine activity. In some human challenge studies, antibody titers of ≥1:40 have been associated with protection from influenza illness in up to 50% of subjects.1,2 Antibody against one influenza virus type or subtype confers little or no protection against another virus. Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. Frequent development of antigenic variants through antigenic drift is the virological basis for seasonal epidemics and the reason for the usual change of one or more new strains in each year’s influenza vaccine. Therefore, inactivated influenza vaccines are standardized to contain the hemagglutinins of strains (i.e., typically 2 type A and 1 type B), representing the influenza viruses likely to circulate in the United States in the upcoming winter.

    Annual revaccination is recommended because immunity declines during the year after vaccination, and because circulating strains of influenza virus change from year to year.3

    13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    FLULAVAL has not been evaluated for carcinogenic or mutagenic potential. Vaccination of female rats with FLULAVAL, at doses shown to be immunogenic in the rat, had no effect on fertility.

    14 CLINICAL STUDIES

    The effectiveness of FLULAVAL was demonstrated based on clinical endpoint efficacy data for FLULAVAL QUADRIVALENT (Influenza Virus Vaccine), clinical endpoint efficacy data for FLULAVAL, and on an evaluation of serum HI antibody responses to FLULAVAL. FLULAVAL QUADRIVALENT, an inactivated influenza virus vaccine that contains the hemagglutinins of two influenza A subtype viruses and two influenza type B viruses, is manufactured according to the same process as FLULAVAL.

    14.1 Efficacy Against Influenza

    Efficacy Trial in Children: The efficacy of FLULAVAL QUADRIVALENT was evaluated in Study 5, a randomized, observer-blind, non-influenza vaccine-controlled study conducted in 3 countries in Asia, 3 in Latin America, and 2 in the Middle East/Europe during the 2010-2011 influenza season. Healthy subjects 3 through 8 years of age were randomized (1:1) to receive FLULAVAL QUADRIVALENT (N = 2,584), containing A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Florida/4/2006 (Yamagata lineage) influenza strains, or HAVRIX® (Hepatitis A Vaccine) (N = 2,584), as a control vaccine. Children with no history of influenza vaccination received 2 doses of FLULAVAL QUADRIVALENT or HAVRIX approximately 28 days apart. Children with a history of influenza vaccination received one dose of FLULAVAL QUADRIVALENT or HAVRIX. In the overall population, 52% were male; 60% were Asian, 5% were White, and 35% were of other racial/ethnic groups. The mean age of subjects was 5 years.

    Efficacy of FLULAVAL QUADRIVALENT was assessed for the prevention of reverse transcriptase polymerase chain reaction (RT-PCR)-positive influenza A and/or B disease presenting as influenza-like illness (ILI). ILI was defined as a temperature ≥100°F in the presence of at least one of the following symptoms on the same day: cough, sore throat, runny nose, or nasal congestion. Subjects with ILI (monitored by passive and active surveillance for approximately 6 months) had nasal and throat swabs collected and tested for influenza A and/or B by RT-PCR. All RT-PCR-positive specimens were further tested in cell culture. Vaccine efficacy was calculated based on the ATP cohort for efficacy (Table 4).

    Nb nc Influenza Attack Rate % (n/N)Vaccine Efficacy
  • % (CI)All RT-PCR-Positive InfluenzaFLULAVAL QUADRIVALENT2,379582.455.4d
  • (95% CI: 39.1, 67.3)HAVRIXe2,3981285.3–All Culture-Confirmed Influenzaf FLULAVAL QUADRIVALENT2,379502.155.9
  • (97.5% CI: 35.4, 69.9)HAVRIXe2,3981124.7–Antigenically Matched Culture-Confirmed InfluenzaFLULAVAL QUADRIVALENT2,379311.345.1g
  • (97.5% CI: 9.3, 66.8)HAVRIXe2,398562.3–
    Table 4. FLULAVAL QUADRIVALENT: Influenza Attack Rates and Vaccine Efficacy Against Influenza A and/or B in Children 3 Through 8 Years of Agea (According to Protocol Cohort for Efficacy)
     
     
     
       
     
     
     
     
     
       
     
     
     
     
     
     
     
     
     
     
       
     
     
     
     
     
     
     
     
     
     
       
     
     
     
     
     

    CI = Confidence Interval; RT-PCR = reverse transcriptase polymerase chain reaction.

    a Study 5: NCT01218308.

    b According to protocol cohort for efficacy included subjects who met all eligibility criteria, were successfully contacted at least once post-vaccination, and complied with the protocol-specified efficacy criteria.

    c Number of influenza cases.

    d Vaccine efficacy for FLULAVAL QUADRIVALENT met the pre-defined criterion of >30% for the lower limit of the 2-sided 95% CI.

    e Hepatitis A Vaccine used as a control vaccine.

    f Of 162 culture-confirmed influenza cases, 108 (67%) were antigenically typed (87 matched; 21 unmatched); 54 (33%) could not be antigenically typed [but were typed by RT-PCR and nucleic acid sequence analysis: 5 cases A (H1N1) (5 with HAVRIX), 47 cases A (H3N2) (10 with FLULAVAL QUADRIVALENT; 37 with HAVRIX), and 2 cases B Victoria (2 with HAVRIX)].

    g Since only 67% of cases could be typed, the clinical significance of this result is unknown.

    In an exploratory analysis by age, vaccine efficacy against RT-PCR-positive influenza A and/or B disease presenting as ILI was evaluated in subjects 3 through 4 years of age and 5 through 8 years of age; vaccine efficacy was 35.3% (95% CI: ‑1.3, 58.6) and 67.7% (95% CI: 49.7, 79.2), respectively. As the study lacked statistical power to evaluate efficacy within age subgroups, the clinical significance of these results is unknown.

    As a secondary objective in the study, subjects with RT-PCR-positive influenza A and/or B were prospectively classified based on the presence of adverse outcomes that have been associated with influenza infection (defined as fever >102.2°F/39.0°C, physician-verified shortness of breath, pneumonia, wheezing, bronchitis, bronchiolitis, pulmonary congestion, croup and/or acute otitis media, and/or physician-diagnosed serious extra-pulmonary complications, including myositis, encephalitis, seizure and/or myocarditis).

    The risk reduction of fever >102.2°F/39.0°C associated with RT-PCR-positive influenza was 71.0% (95% CI: 44.8, 84.8) based on the ATP cohort for efficacy [FLULAVAL QUADRIVALENT (n = 12/2,379); HAVRIX (n = 41/2,398)]. The other pre-specified adverse outcomes had too few cases to calculate a risk reduction. The incidence of these adverse outcomes is presented in Table 5.

    FLULAVAL
  • QUADRIVALENT
  • N = 2,584HAVRIXc
  • N = 2,584Adverse Outcomed Number of EventsNumber of Subjectse %Number of EventsNumber of Subjectse %Fever >102.2°F/39.0°C16f150.651f501.9Shortness of breath000550.2Pneumonia000330.1Wheezing110110Bronchitis110110Pulmonary congestion000110Acute otitis media000110Bronchiolitis000000Croup000000Encephalitis000000Myocarditis000000Myositis000000Seizure000000
    Table 5. FLULAVAL QUADRIVALENT: Incidence of Adverse Outcomes Associated With RT-PCR-Positive Influenza in Children 3 Through 8 Years of Agea (Total Vaccinated Cohort)b
         
       
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     

    a Study 5: NCT01218308.

    b Total vaccinated cohort included all vaccinated subjects for whom data were available.

    c Hepatitis A Vaccine used as a control vaccine.

    d In subjects who presented with more than one adverse outcome, each outcome was counted in the respective category.

    e Number of subjects presenting with at least one event in each group.

    f One subject in each group had sequential influenza due to influenza type A and type B viruses.

    Efficacy Trial in Adults: The efficacy of FLULAVAL was evaluated in a randomized, double-blind, placebo-controlled study conducted in the United States during the 2005-2006 and 2006-2007 influenza seasons (Study 3). Efficacy of FLULAVAL was defined as the prevention of culture-confirmed influenza A and/or B cases, for vaccine antigenically matched strains, compared with placebo. Healthy subjects 18 through 49 years of age were randomized (1:1); a total of 3,783 subjects received FLULAVAL and 3,828 subjects received placebo [see Adverse Reactions (6.1)]. Subjects were monitored for influenza-like illnesses (ILI) starting 2 weeks post-vaccination and for duration of approximately 7 months thereafter. Culture-confirmed influenza was assessed by active and passive surveillance of ILI. Influenza-like illness was defined as illness sufficiently severe to limit daily activity and including cough, and at least one of the following: Fever >99.9°F, nasal congestion or runny nose, sore throat, muscle aches or arthralgia, headache, feverishness or chills. After an episode of ILI, nose and throat swab samples were collected for analysis; attack rates and vaccine efficacy were calculated using the per protocol cohort (Table 6). Of note, the 1.2% attack rate in the placebo group for culture-confirmed, antigenically matched strains was lower than expected, contributing to a wide confidence interval for the estimate of vaccine efficacy.

    Influenza Attack RatesVaccine EfficacyNb nc % (n/N)%97.5% CI
  • Lower LimitAntigenically Matched StrainsFLULAVAL3,714230.646.39.8dPlacebo3,768451.2––All Culture-Confirmed Influenza (Matched, Unmatched, and Untyped)FLULAVAL3,714300.849.320.3Placebo3,768601.6––
    Table 6. FLULAVAL: Influenza Attack Rates and Vaccine Efficacy Against Culture-Confirmed Influenza in Adults 18 Through 49 Years of Agea (Per Protocol Cohort)
     
     
     
     
     
     
       
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     

    CI = Confidence Interval.

    •   a Study 3: NCT00216242.
    •   b Per Protocol Cohort for efficacy included subjects with no protocol deviations considered to compromise efficacy data.
    •   c Number of influenza cases.
    •   d Lower limit of the one-sided 97.5% CI for vaccine efficacy against influenza due to antigenically matched strains was less than the pre-defined success criterion of ≥35%.

    14.2 Immunological Evaluation

    Adults: Study 1 was a randomized, blinded, active-controlled US study performed in healthy adults 18 through 64 years of age (N = 1,000). A total of 721 subjects received FLULAVAL, and 279 received a US‑licensed trivalent, inactivated influenza virus vaccine, FLUZONE (manufactured by Sanofi Pasteur SA), intramuscularly; 959 subjects had complete serological data and no major protocol deviations [see Adverse Reactions (6.1)].

    Analyses of immunogenicity (Table 7) were performed for each hemagglutinin (HA) antigen contained in the vaccine: 1) assessment of the lower bounds of 2‑sided 95% confidence intervals for the proportion of subjects with HI antibody titers of ≥1:40 after vaccination, and 2) assessment of the lower bounds of 2-sided 95% confidence intervals for rates of seroconversion (defined as a 4‑fold increase in post-vaccination HI antibody titer from pre-vaccination titer ≥1:10, or an increase in titer from <1:10 to ≥1:40). The pre-specified success criteria for HI titer ≥1:40 was 70% and for seroconversion rate was 40%. The lower limit of the 2-sided 95% CI for the percentage of subjects who achieved an HI titer of ≥1:40 exceeded the pre-defined criteria for the A strains. The lower limit of the 2-sided 95% CI for the percentage of subjects who achieved seroconversion exceeded the pre-defined criteria for all 3 strains.

    Table 7. Immune Responses to Each Antigen 21 Days After Vaccination With FLULAVALa in Adults 18 Through 64 Years of Age (Per Protocol Cohort)b

    FLULAVAL

    N = 692

    % of Subjects (95% CI)

    HI titers ≥1:40

    Pre-vaccination

    Post-vaccination

    A/New Caledonia/20/99 (H1N1)

    24.6

    96.5 (94.9, 97.8)

    A/Wyoming/03/03 (H3N2)

    58.7

    98.7 (97.6, 99.4)

    B/Jiangsu/10/03

    5.4

    62.9 (59.1, 66.5)

    Seroconversionc to:

    A/New Caledonia/20/99 (H1N1)

    85.6 (82.7, 88.1)

    A/Wyoming/03/03 (H3N2)

    79.3 (76.1, 82.3)

    B/Jiangsu/10/03

    58.4 (54.6, 62.1)

    HI – hemagglutination inhibition; CI = Confidence Interval.

    •   a Results obtained following vaccination with FLULAVAL manufactured for the 2004–2005 season.
    •   b Per Protocol Cohort for immunogenicity included subjects with complete pre- and post-dose HI titer data and no major protocol deviations.
    •   c Seroconversion defined as a 4‑fold increase in post-vaccination HI antibody titer from pre-vaccination titer ≥1:10, or an increase in titer from <1:10 to ≥1:40.

    Study 2 (Immunogenicity Non-Inferiority): In a randomized, double-blind, active-controlled US study, immunological non-inferiority of FLULAVAL was compared with a US‑licensed trivalent, inactivated influenza virus vaccine, FLUZONE, manufactured by Sanofi Pasteur SA. A total of 1,225 adults ≥50 years of age and older in stable health were randomized to receive FLULAVAL or the comparator vaccine intramuscularly [see Adverse Reactions (6.1)].

    Analyses of immunogenicity were performed for each HA antigen contained in the vaccines: 1) assessment of the lower bounds of 2‑sided 95% confidence intervals for the geometric mean antibody titer (GMT) ratio (FLULAVAL/comparator), and 2) assessment of the lower bounds of 2‑sided 95% confidence intervals for seroconversion rates (defined as a 4‑fold increase in post-vaccination HI antibody titer from pre-vaccination titer ≥1:10, or an increase in titer from <1:10 to ≥1:40). Non-inferiority of FLULAVAL to the comparator vaccine was established for all 6 co-primary endpoints (Table 8). Within each age stratum, immunogenicity results were similar between the groups.

    GMTs AgainstSeroconversione to:
    Table 8. Immune Responses to Each Antigen 21 Days After Vaccination With FLULAVAL Versus Comparator Influenza Vaccine in Adults 50 Years of Age and Oldera (Per Protocol Cohort)b

    FLULAVAL

    N = 592

    Active Comparatorc

    N = 595

     

    GMT

    (95% CI)

    GMT

    (95% CI)

    GMT Ratiod

    (95% CI)

    A/New Caledonia/20/99 (H1N1)

    113.4

    (104.7, 122.8)

    110.2

    (101.8, 119.3)

    1.03

    (0.92, 1.15)

    A/New York/55/04 (H3N2)

    223.9

    (199.5, 251.3)

    214.6

    (191.3, 240.7)

    1.04

    (0.89, 1.23)

    B/Jiangsu/10/03

    82.3

    (74.7, 90.6)

    97.1

    (88.2, 106.8)

    0.85

    (0.74, 0.97)

     

    % of Subjects

    (95% CI)

    % of Subjects

    (95% CI)

    Difference in Seroconversion Ratesf

    (95% CI)

    A/New Caledonia/20/99 (H1N1)

    34

    (30.0, 37.6)

    32

    (28.3, 35.9)

    2

    (-3.7, 7.0)

    A/New York/55/04 (H3N2)

    83

    (80.3, 86.3)

    82

    (78.4, 84.6)

    1

    (-2.6, 6.1)

    B/Jiangsu/10/03

    53

    (49.0, 57.1)

    56

    (51.6, 59.6)

    -3

    (-8.3, 3.1)

    GMT = geometric mean antibody titer; CI = Confidence Interval.

    a Results obtained following vaccination with influenza vaccines manufactured for the 2005‑2006 season.

    b Per Protocol Cohort for immunogenicity included subjects with complete pre- and post-dose HI titer data and no major protocol deviations.

    c US‑licensed trivalent, inactivated influenza virus vaccine (manufactured by Sanofi Pasteur SA).

    d FLULAVAL met non‑inferiority criteria based on GMTs (lower limit of 2‑sided 95% CI for GMT ratio [FLULAVAL/comparator vaccine] ≥0.67).

    e Seroconversion defined as a 4‑fold increase in post-vaccination HI antibody titer from pre-vaccination titer ≥1:10, or an increase in titer from <1:10 to ≥1:40.

    f FLULAVAL met non‑inferiority criteria based on seroconversion rates (lower limit of 2‑sided 95% CI for difference of FLULAVAL minus the comparator vaccine ≥‑10%).

    Children: In Study 4, the immune response of FLULAVAL (N = 987) was compared to FLUZONE, a US‑licensed trivalent, inactivated influenza virus vaccine (N = 979), manufactured by Sanofi Pasteur SA, in an observer-blind, randomized study in children 3 through 17 years of age. The immune responses to each of the antigens contained in FLULAVAL formulated for the 2009-2010 season were evaluated in sera obtained after one or 2 doses of FLULAVAL and were compared to those following the comparator influenza vaccine [see Adverse Reactions (6.1)].

    The non‑inferiority endpoints were geometric mean antibody titers (GMTs) adjusted for baseline, and the percentage of subjects who achieved seroconversion, defined as at least a 4‑fold increase in serum HI titer over baseline to ≥1:40, following vaccination, performed on the According‑to‑Protocol (ATP) cohort. FLULAVAL was non-inferior to the comparator influenza for all strains based on adjusted GMTs and seroconversion rates (Table 9).

    Table 9. Immune Responses to Each Antigen 28 Days After Last Vaccination With FLULAVAL Versus Comparator Influenza Vaccine in Children 3 Through 17 Years of Agea (According to Protocol Cohort for Immunogenicity)b

    FLULAVAL

    Active Comparatorc

    GMTs Against

    N = 987

    (95% CI)

    N = 979

    (95% CI)

    GMT Ratiod

    (95% CI)

    A/Brisbane (H1N1)

    320.9

    (298.3, 345.2)

    329.4

    (306.8, 353.7)

    1.03

    (0.94, 1.13)

    A/Uruguay (H3N2)

    414.7

    (386.5, 444.9)

    451.9

    (423.8, 481.8)

    1.05

    (0.96, 1.13)

    B/Brisbane

    213.7

    (198.5, 230.1)

    200.2

    (186.1, 215.3)

    0.93

    (0.85, 1.02)

    Seroconversione to:

    N = 987

    %

    (95% CI)

    N = 978

    %

    (95% CI)

    Difference in Seroconversion Ratef

    (95% CI)

    A/Brisbane (H1N1)

    59.8

    (56.6, 62.9)

    58.2

    (55.0, 61.3)

    -1.6

    (-5.9, 2.8)

    A/Uruguay (H3N2)

    68.2

    (65.2, 71.1)

    66.2

    (63.1, 69.1)

    -2.0

    (-6.1, 2.1)

    B/Brisbane

    81.1

    (78.5, 83.5)

    78.6

    (75.9, 81.2)

    -2.4

    (-6.0, 1.1)

    GMT = geometric mean antibody titer; CI = Confidence Interval.

    a Results obtained following vaccination with influenza vaccines formulated for the 2009-2010 season.

    b According to protocol cohort for immunogenicity included all evaluable subjects for whom assay results were available after vaccination for at least one study vaccine antigen.

    c US‑licensed trivalent, inactivated influenza virus vaccine (Sanofi Pasteur SA).

    d FLULAVAL met non‑inferiority criteria based on GMTs (upper limit of 2‑sided 95% CI for GMT ratio [comparator vaccine/FLULAVAL] ≤1.5).

    e Seroconversion defined as a 4‑fold increase in post-vaccination HI antibody titer from pre-vaccination titer ≥1:10, or an increase in titer from <1:10 to ≥1:40.

    f FLULAVAL met non‑inferiority criteria based on seroconversion rates (upper limit of 2‑sided 95% CI for difference of the comparator vaccine minus FLULAVAL ≤10%).

    15 REFERENCES

    • 1.Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004;103:133-138.
    • 2.Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg Camb 1972;70:767-777.
    • 3.Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(RR-8):1-62.

    16 HOW SUPPLIED/STORAGE AND HANDLING

    FLULAVAL is supplied in a 5-mL multi-dose vial containing 10 doses (0.5-mL each).

    NDC 19515-890-02 Vial (containing 10 doses) in Package of 1: NDC 19515-890-07

    Once entered, a multi-dose vial should be discarded after 28 days. Store refrigerated between 2º and 8ºC (36º and 46ºF). Do not freeze. Discard if the vaccine has been frozen. Store in the original package to protect from light.

    17 PATIENT COUNSELING INFORMATION

    Provide the following information to the vaccine recipient or guardian:

    • •Inform of the potential benefits and risks of immunization with FLULAVAL.
    • •Educate regarding potential side effects, emphasizing that: (1) FLULAVAL contains non-infectious killed viruses and cannot cause influenza, and (2) FLULAVAL is intended to provide protection against illness due to influenza viruses only, and cannot provide protection against all respiratory illness.
    • •Instruct to report any adverse events to their healthcare provider.
    • •Inform that safety and efficacy have not been established in pregnant women. Register women who receive FLULAVAL while pregnant in the pregnancy registry by calling 1-888-452-9622.
    • •Give the Vaccine Information Statements, which are required by the National Childhood Vaccine Injury Act of 1986 prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (www.cdc.gov/vaccines).
    • •Instruct that annual revaccination is recommended.

    FLULAVAL and HAVRIX are registered trademarks of GlaxoSmithKline. FLUZONE is a registered trademark of Sanofi Pasteur Limited.

    Manufactured by ID Biomedical Corporation of Quebec

    Quebec City, QC, Canada, US License 1739

    Distributed by GlaxoSmithKline

    Research Triangle Park, NC 27709

    ©2013, GlaxoSmithKline. All rights reserved.

    FLV:12PI

    Principal Display Panel

    NDC 19515-889-07

    Influenza Virus Vaccine

    FLULAVAL®

    2012/2013 Formula

    5 mL vial (10 doses)

    Single-Dose: 0.5 mL

    For Adult Use Only

    Rx only

    GlaxoSmithKline

    Rev. 4/12

    453458

    Principal Display Panel

    NDC 19515-890-07

    Influenza Virus Vaccine

    FLULAVAL®

    2013/2014 Formula

    5 mL vial (10 doses)

    Single-Dose: 0.5 mL

    For Adult Use Only

    Rx only

    GlaxoSmithKline

    Rev 2/13

    460798

    FLULAVAL

    influenza virus vaccine SUSPENSION

    Product Information

    Product Type Vaccine label Item Code (Source) NDC:19515-889
    Route of Administration INTRAMUSCULAR DEA Schedule

    Active Ingredient/Active Moiety

    Ingredient Name Basis of Strength Strength
    INFLUENZA A VIRUS A/CALIFORNIA/7/2009 X-179A (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED) INFLUENZA A VIRUS A/CALIFORNIA/7/2009 X-179A (H1N1) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug
    INFLUENZA A VIRUS A/VICTORIA/361/2011 IVR-165 (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED) INFLUENZA A VIRUS A/VICTORIA/361/2011 IVR-165 (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug
    INFLUENZA B VIRUS B/HUBEI-WUJIAGANG/158/2009 BX-39 ANTIGEN (UV, FORMALDEHYDE INACTIVATED) INFLUENZA B VIRUS B/HUBEI-WUJIAGANG/158/2009 BX-39 HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug

    Inactive Ingredients

    Ingredient Name Strength
    THIMEROSAL
    MERCURY

    Packaging

    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:19515-889-02 5 in 1 VIAL, MULTI-DOSE
    2 NDC:19515-889-07 1 in 1 CARTON

    Marketing Information

    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA125163 2012-07-20


    FLULAVAL

    influenza virus vaccine SUSPENSION

    Product Information

    Product Type Vaccine label Item Code (Source) NDC:19515-890
    Route of Administration INTRAMUSCULAR DEA Schedule

    Active Ingredient/Active Moiety

    Ingredient Name Basis of Strength Strength
    INFLUENZA A VIRUS A/CALIFORNIA/7/2009 X-179A (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED) INFLUENZA A VIRUS A/CALIFORNIA/7/2009 X-179A (H1N1) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug
    INFLUENZA A VIRUS A/TEXAS/50/2012 X-223A (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED) INFLUENZA A VIRUS A/TEXAS/50/2012 X-223A (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug
    INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 BX-51B ANTIGEN (UV, FORMALDEHYDE INACTIVATED) INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 BX-51B HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug

    Inactive Ingredients

    Ingredient Name Strength
    THIMEROSAL
    MERCURY

    Packaging

    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:19515-890-02 5 in 1 VIAL, MULTI-DOSE
    2 NDC:19515-890-07 1 in 1 CARTON

    Marketing Information

    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA125163 2013-07-01


    PLEASE, BE CAREFUL!
    Be sure to consult your doctor before taking any medication!
    Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
    Support info@drugs-library.com.